|RxNews Recap for Wednesday 12-16-09|
|By Mary Davila|
|Wednesday, 16 December 2009 19:54|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.
Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today that Bristol-Myers Squibb has set the exchange ratio for its offer to exchange up to 170.0 million shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that are validly tendered and not validly withdrawn.
Boston Scientific Corporation (NYSE:BSX) today announced that the Company's Board of Directors has elected Nelda Connors as a Director.
Catalyst Rx, the pharmacy benefit management (PBM) subsidiary of Catalyst Health Solutions, Inc. (NASDAQ: CHSI), announced today that Michigan’s State Administrative Board has formally approved Catalyst Rx to provide PBM services for The Michigan Public School Employees Retirement System beginning January 1, 2010.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has reduced its debt by a total of $1.4 million so far in the fourth quarter of 2009 and total debt eliminated for the year now tops $10 million.
Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit, for gross proceeds of $6.4 million before deducting underwriting discounts and commissions and estimated offering expenses.
InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients.
Merck & Co., Inc. (NYSE:MRK) today announced the appointment of Dr. Michael Rosenblatt as Executive Vice President and Chief Medical Officer, effective immediately.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.
Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, announced today the sale and installation of its PET scanner to Manhattan based, Gramercy Cardiac Diagnostic Services, owned by prominent New York City cardiologist, Dr. Peter Rentrop.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has licensed its P2X31 receptor program aimed at developing first-in-class treatment for chronic pain to Afferent Pharmaceuticals.
Unilife Medical Solutions Limited (Unilife or the Company) (ASX: UNI) (PINKSHEETS: UNIFF) today announced the signing of agreements for the construction of its new global headquarters and commercial production facility in York, Pennsylvania.
USACIG, Inc. and Hop-on, Inc. (PINKSHEETS:HPNN) are proud to announce that USACIG has signed an exclusive agreement with Hop-on, Inc. to submit its Electric Cigarette Nicotine water technology to the FDA for clinical studies for the prevention of Parkinson's disease and for the alleviation of its symptoms.
TRIMEDYNE, INC. (OTCBB: TMED) today announced its chairman, Marvin P. Loeb, Sc.D., was interviewed live by CEO NEWS.
Sequenom, Inc. (Nasdaq: SQNM), today announced the appointment of Dr. Kenneth Buechler and Mr. David Pendarvis to its board of directors.
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software to the pharmaceutical industry, announces the appointment of Mr. John DiBella as manager of marketing and sales, reporting to Dr. Michael Pelekis, director of business development, marketing, and sales.
Walgreens (NYSE, NASDAQ: WAG), the nation’s largest drugstore chain and an industry leader with more than 17,000 certified or licensed immunizers, today announced it is offering H1N1 vaccine at more than 1,500 Walgreens pharmacies and select Take Care Clinics in 27 states, as well as the District of Columbia.